{"ticker": {"uuid": "0562e666-b566-4efb-a281-9d1639b1ee1d", "symbol": "ANGO", "name": "AngioDynamics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Medical Instruments & Supplies"}, "articles": [{"title": "AngioDynamics rises as Freedom Broker raises stock price target to $17", "summary": "Freedom Broker analysts have raised their price target for AngioDynamics (ANGO) to $17, maintaining a \"Buy\" rating, following strong financial results. The NanoKnife platform is highlighted as a key growth driver, with expanded insurance coverage and increased disposable use. The", "url": "https://fbroker.kz/en/news/50993-angiodynamics-rises-as-freedom-broker-raises-stock-price-target-to-17-en-2", "source_name": "Freedom Broker", "published_at": "2026-07-16T18:42:19", "published_display": "16 Jul 2026 18:42", "sentiment": "positive", "sentiment_pct": 81, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics: Growth Is Working, Price Knows It (Rating Downgrade)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOWXZjMTloZVo2N1pCN0d3R1Y4a1hqMktoT1ZZUTB2dV9KZ2VyQ09XNV9XMWNfS01hZkZrcXdaVm1ETXJTLTFSc3h0MFVma3N5Vkd4VjZnRTlmTmZSaWpmRW14c25PSW9qNy1JWFVfX0VFY1AtamRGekZvNHZ1N2xoNlBYWjZLTkV1dktOYmVhclpOVVJCR2FGVzAwU1ZreEpZQlMw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-16T15:07:15+00:00", "published_display": "16 Jul 2026 15:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Maintains AngioDynamics(ANGO.US) With Buy Rating, Maintains Target Price $19", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNcHdIUkNXSkc4WkhQR0Y3MUhSamZIMmZRTjJrYkwzeXBJY3otaWNCNTRicWF6RjFOR2M0am96aUt3RGRQUWx3QmdPMk5zOEppMkFSRG9oWXpNaWQweUVhcUxuSm1lTGRqVGdOR0Jld2xwLTJHTmVKVWRpc1YxYTZfcUV5Z1ZGMUo0UEY3eDlIc1g3bUZJQWhjWnZGaEQ5OTRWc1J6NE9UaE15WUJLUFFzMHVSVFQ5Zm1uUnFB?oc=5", "source_name": "Moomoo", "published_at": "2026-07-16T12:14:45+00:00", "published_display": "16 Jul 2026 12:14", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright raises AngioDynamics stock price target on growth", "summary": "H.C. Wainwright has increased its price target for AngioDynamics (NASDAQ:ANGO) shares to $19 from $16, maintaining a Buy rating, following the company's strong fiscal fourth-quarter and full-year 2026 results. The medical technology firm reported significant growth in net sales, ", "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-raises-angiodynamics-stock-price-target-on-growth-93CH-4795558", "source_name": "Investing.com", "published_at": "2026-07-16T11:41:36", "published_display": "16 Jul 2026 11:41", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics (ANGO) Stock Faces Profitability Question As Q4 EPS Loss Deepens Bearish Narrative", "summary": "AngioDynamics (ANGO) concluded FY 2026 with a Q4 basic EPS loss of US$0.27 and a full-year basic EPS loss of US$0.88 on US$320.2 million in revenue, continuing a trend of net losses. While forecasts project 72.2% annual earnings growth and profitability within three years, the co", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-ango/angiodynamics/news/angiodynamics-ango-stock-faces-profitability-question-as-q4/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-16T01:13:40", "published_display": "16 Jul 2026 01:13", "sentiment": "negative", "sentiment_pct": 29, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics 4Q Loss/Shr 27c >ANGO", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxOaTNsbDJCNWJyTVRVMG15VnVnNThQNW1hSjQxYkFla1V5TmxjZFBWeV9zaVlra21HYnlvZnRPa0lSd0VYOUZzNDdHM3NyYXZ2WDhTbkpONnRNQ1Zuck1hcXh1aWVzQW5UVDcxTUQ4THl6d3ZYM2l4WUpEdjJfZWRYOWxB?oc=5", "source_name": "Moomoo", "published_at": "2026-07-15T23:36:58+00:00", "published_display": "15 Jul 2026 23:36", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Freedom Broker raises AngioDynamics stock price target to $17 on margin outlook", "summary": "Freedom Broker increased its price target for AngioDynamics (NASDAQ: ANGO) to $17.00 from $16.00, reiterating a Buy rating due to an improved margin outlook. This revision follows an upward adjustment of fiscal 2027 adjusted EBITDA estimates by 29% and expectations of growing mar", "url": "https://www.investing.com/news/analyst-ratings/freedom-broker-raises-angiodynamics-stock-price-target-to-17-on-margin-outlook-93CH-4793769", "source_name": "Investing.com", "published_at": "2026-07-15T15:43:40", "published_display": "15 Jul 2026 15:43", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics Q4 Earnings Beat Estimates, Gross Margin Expands", "summary": "AngioDynamics (ANGO) reported an adjusted loss per share of 7 cents for Q4 fiscal 2026, which was narrower than analysts' expectations, and full-year fiscal 2026 adjusted loss also beat estimates. The company's Q4 revenues rose 8% year-over-year to $86.6 million, exceeding the Za", "url": "https://www.tradingview.com/news/zacks:33dbbdd2c094b:0-angiodynamics-q4-earnings-beat-estimates-gross-margin-expands/", "source_name": "TradingView", "published_at": "2026-07-15T14:43:40", "published_display": "15 Jul 2026 14:43", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics (NASDAQ: ANGO) details device portfolio and risk factors", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOcHlpWDBLTW1QMUVkOEFfVXdkWDQxU0g2dzh2V3VYa0xrTXRoTlh1RUVYLW1VcE5GZVl1M2EzWDhQcnJ1LU5XejhfX1ZZMUF5R2JBVVVpT0kwLS1FWEpkbE5VUHE3a0xFNkxlODk3VFR2VngzcWpqN0l2NnJnSm5IbWZDY2VITnRSOHhOaHRscm5YdXZhSjVzZzg2OE9CRWhRVzItSlZ0WQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-14T20:01:03+00:00", "published_display": "14 Jul 2026 20:01", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics Inc (ANGO) Q4 2026 Earnings Call Highlights: Strong Revenue Growth Amidst Challenges", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/angiodynamics-inc-ango-q4-2026-190032475.html", "source_name": "GuruFocus.com", "published_at": "2026-07-14T19:00:32+00:00", "published_display": "14 Jul 2026 19:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANGIODYNAMICS INC FY 2026: Revenue $320.17M, EPS ($0.88) \u2014 10-K Summary", "summary": "AngioDynamics Inc. reported fiscal year 2026 revenue of $320.17M, a 9.5% increase from the previous year, with a net loss of ($36.74M) and diluted loss per share of ($0.88). The revenue growth was primarily driven by Med Tech, and the company is restructuring its manufacturing fo", "url": "https://www.tradingview.com/news/tradingview:0e756c4cf93a3:0-angiodynamics-inc-fy-2026-revenue-320-17m-eps-0-88-10-k-summary/", "source_name": "TradingView", "published_at": "2026-07-14T19:40:08", "published_display": "14 Jul 2026 19:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics Q4 2026 Earnings Call Transcript", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxQQVdpdkhsYzc3MWFCV3l2MkhlNFFUZFdiNFJKRExlV3lvUlNXU3p5QjlvZ19rWU04WXZxWEg2azVvazZfVm80U0didnh2ZzVjMUlNRzVkNF9ORXFLYTlzT21wXzkwcy1NOS1uaHlPTXV1QXBlNmVZV2NuaUdzSnRZY3ZkcUM?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-14T17:12:21+00:00", "published_display": "14 Jul 2026 17:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is AngioDynamics Inc (ANGO) Overvalued After Q4 Earnings Miss? E", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxQS2F1cTBoWjBYTGhZQWptUndkWjl1NEVDWDZmR0ZJZ1J5UUZSbE9GQWIwbE1vT25NZDdvak9mbm96ZzJWdnNRQVZXckEtYzlpUmlrQXpKT1k4QzJ3Sm1yT3B3RkJ6bGlEcWdfZWdmX0FFX0N0dWhVbUx2SEcycVkzLXVYUnZzRG4wbk1Fa0tqaGpiQnJYc1JrQzdydTJjbTBaTTNDS3BwdE5oU3FUeklTYjdJazlXbmxRNVNSRlhTSmdSOEtienhxWnU4MDZfZU5HXzl5d2ZmUWZwdjJqUlNZcXNZdllHSFhoWGVrYlNvVDY?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-14T13:33:55+00:00", "published_display": "14 Jul 2026 13:33", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: AngioDynamics beats Q4 2026 estimates, shares rise", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxNS1FDSjdQOFlCc1hlMVJlNldrUEpFcWhqUFZZMEE3VUNDUVlZQXBCWlQ5X3FsMi01V1ZmU0EtODFrdDk1SnR0Ujc2Vlo4bHl4amtMZWxNb1NjRVI3NXZxbEd3Q2hKQTFUMmVTSTJRb19TQnJmdzZOblhJZzNRck5nd0IyU1FDd3hheVhzbkJJZ3RxcnRKMHZONHoyUFJmWXJpSTRzMzJ0dUo4V3pBMDJnODRrMFlmNzVoNml2RHJMbUhzaEJ5Z1hMVlp3?oc=5", "source_name": "Investing.com", "published_at": "2026-07-14T13:25:56+00:00", "published_display": "14 Jul 2026 13:25", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics Q4 Earnings Call Highlights", "summary": "", "url": "https://finance.yahoo.com/m/4216e10c-f951-375d-873d-0df91320a7c6/angiodynamics-q4-earnings.html", "source_name": "MarketBeat", "published_at": "2026-07-14T13:03:07+00:00", "published_display": "14 Jul 2026 13:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics, Inc. 2026 Q4 - Results - Earnings Call Presentation (NASDAQ:ANGO) 2026-07-14", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNWDdzbVZ6WDVDOVoxRzRjeXFyV2c2bXBwNmZYUFgxUHNwd0dyeTJFeVNvaHRZS3NoWVFXRUJKNFdZYWhQa2RRWkIwTDQtMHBvbnV1MHNmR2hOSXMybFBrTnpZM1lFdmVuTEl1ek5EQURmTjFWaHFSZktSUWpWM29BNzIxeEsxZjczVWUtakRxTnFHWUtsOGtMUTdKNTdlZHpYZGJN?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-14T12:31:57+00:00", "published_display": "14 Jul 2026 12:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics tops revenue forecasts and raises sales outlook for fiscal 2027 (ANGO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9AFBVV95cUxPenlCdmhNVFZuZWQxOGtELUxNQmZHcXc2UWxXODVTU1FYSDlGVUpzS05QSlBBS3ZPZ1ZFVUJIQ2thYzlEcGszbUhKd3dNakFEdUFmV3BrdmlnY1MtMkFwQWEwSE05YlFHeUtSQTJKUXpTZlNxUzhTcnFZOXcwUklOZUVzYVRseS1fdjgyYXNmTmR6X1RlZW9vWFJSOTlwRUtIQ3EzVHRab0pBdW1UNm1sM0gzRjJBcUdHRmttTGtuM0V0MGlxUlhUUkl2dTdTX3JuS2Nvdm5MZzBJQUU2UUNiSzFxM1QwM2JadmU4Q2xDT2tsMHZT?oc=5", "source_name": "MSN", "published_at": "2026-07-14T11:39:57+00:00", "published_display": "14 Jul 2026 11:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics Releases Q4 2026 Financial Results", "summary": "AngioDynamics, Inc. (ANGO) reported Q4 2026 adjusted diluted loss per share of -$0.07, outperforming the -$0.09 expected loss. The company's revenue reached $86.6 million, surpassing the consensus estimate by 7.9% and marking an 8% year-over-year increase. AngioDynamics also prov", "url": "https://news.alphastreet.com/angiodynamics-releases-q4-2026-financial-results/", "source_name": "AlphaStreet", "published_at": "2026-07-14T12:23:25", "published_display": "14 Jul 2026 12:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics (ANGO) Reports Q4 Loss, Beats Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNb2R0ZTJ2RkJvbW9WbE5YTXNfM1pZWEx4NjlNVGNkZzhYOG90a2tpWTRabEhhaUJQV0lPQWNadnlocFcydGhKQ2dMV3dGYWdFSC1uMENTZjhIVVlXMTdrZ09GZzRYVG1tYmlYOXlfVURvMnJRaWlNdURDYnhZN2dUclBRSTNzRlRObFpRa25vVUFDTnRyczhPTXRydzZhTVha?oc=5", "source_name": "Market source", "published_at": "2026-07-14T11:15:02+00:00", "published_display": "14 Jul 2026 11:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANGIODYNAMICS ($ANGO) Releases Q4 2026 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxNaGw3SC1qWDNDdjhlbEZKcm9mVVdleGk2QUtTWVF3U1R3dVc4VlVDbHZKdF9XNmVTanJGdkQyWUZqbnF0dDhRME9zTDY3TWQ2aGtZWENTVDdnSEo3M2xJb1dCQnFZNExXWmJCM3VzdDlMV2NaMkNROHhfS1RzMUtyY2xoYUNZRUJjNmp3Mm1yRQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-14T10:30:00+00:00", "published_display": "14 Jul 2026 10:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Record 2026 sales as AngioDynamics (NASDAQ: ANGO) grows Med Tech 18%", "summary": "AngioDynamics (NASDAQ: ANGO) reported record fiscal 2026 results with pro forma net sales of $320.2 million, a 9.4% increase, driven by an 18.4% rise in Med Tech revenue. Despite a GAAP net loss of $36.7 million, adjusted EBITDA increased to $13.2 million. The company issued fisc", "url": "https://www.stocktitan.net/sec-filings/ANGO/8-k-angiodynamics-inc-reports-material-event-12136bb69c7f.html", "source_name": "Stock Titan", "published_at": "2026-07-14T11:14:25", "published_display": "14 Jul 2026 11:14", "sentiment": "positive", "sentiment_pct": 69, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results; Continued Execution Drives Med Tech Growth and Full-Year Profitability", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/angiodynamics-reports-record-fiscal-2026-100000723.html", "source_name": "Business Wire", "published_at": "2026-07-14T10:00:00+00:00", "published_display": "14 Jul 2026 10:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NanoKnife Medicare Coverage Takes Effect for Qualifying Patients", "summary": "AngioDynamics (NASDAQ: ANGO) announced its fourth quarter and full fiscal year 2026 financial results, highlighting a year of consistent execution and significant growth in its Med Tech segment. The company reported full-year Med Tech growth over 18%, driven by platform technolog", "url": "https://www.stocktitan.net/news/ANGO/angio-dynamics-reports-record-fiscal-year-2026-fourth-quarter-and-yawzx4si7ilh.html", "source_name": "Stock Titan", "published_at": "2026-07-14T10:14:25", "published_display": "14 Jul 2026 10:14", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: AngioDynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results", "summary": "AngioDynamics reported record financial results for its fiscal year 2026 fourth quarter and full year. The company saw strong performance driven by its innovative medical technologies. These results highlight a period of significant growth and market penetration for AngioDynamics", "url": "https://www.moomoo.com/news/post/72924322/press-release-angiodynamics-reports-record-fiscal-year-2026-fourth-quarter?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-14T10:14:25", "published_display": "14 Jul 2026 10:14", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics: Fiscal Q4 Earnings Snapshot", "summary": "AngioDynamics Inc. (ANGO) reported a fiscal fourth-quarter loss of $11.4 million, or 27 cents per share, with adjusted losses at 7 cents per share. The medical device maker posted revenue of $86.6 million for the quarter. For the full year, the company's loss widened to $36.7 mil", "url": "https://www.10tv.com/article/syndication/associatedpress/angiodynamics-fiscal-q4-earnings-snapshot/616-5559f4da-9b02-4d23-9dea-65e182193575", "source_name": "10TV", "published_at": "2026-07-14T06:18:00", "published_display": "14 Jul 2026 06:18", "sentiment": "negative", "sentiment_pct": 32, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics Inc expected to post a loss of 9 cents a share - Earnings Preview", "summary": "AngioDynamics Inc is projected to report a loss of 9 cents per share, according to this earnings preview. The article, sourced from Reuters, specifically highlights the anticipated financial performance for the company. Readers are prompted to start a free trial to access the ful", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_L8N43C0WC:0-angiodynamics-inc-expected-to-post-a-loss-of-9-cents-a-share-earnings-preview/", "source_name": "TradingView", "published_at": "2026-07-10T12:40:48", "published_display": "10 Jul 2026 12:40", "sentiment": "negative", "sentiment_pct": 28, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vortex Port Lawsuit Claims Defective AngioDynamics Device Caused Infection, Pulmonary Embolism", "summary": "A South Carolina woman has filed a lawsuit against AngioDynamics and Navilyst Medical Inc., alleging that their defective Vortex port catheter caused her to suffer pulmonary embolisms and a serious infection, necessitating its surgical removal. The complaint claims the defendants", "url": "https://www.aboutlawsuits.com/angiodynamics-port-catheter-lawsuit/vortex-port-lawsuit-defective-angiodynamics-device-infection-pulmonary-embolism/", "source_name": "AboutLawsuits.com", "published_at": "2026-07-07T15:11:00", "published_display": "07 Jul 2026 15:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics (Nasdaq:ANGO) - Stock Analysis", "summary": "This report provides a comprehensive stock analysis of AngioDynamics (Nasdaq:ANGO), detailing its financial performance, future growth prospects, and recent developments. The company, a medical technology firm specializing in devices for peripheral vascular disease and oncology, ", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-ango/angiodynamics", "source_name": "Simply Wall Street", "published_at": "2026-07-07T11:40:01", "published_display": "07 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of AngioDynamics, Inc. \u2013 NASDAQ:ANGO", "summary": "This article provides the \"Price to earnings forward\" value for AngioDynamics, Inc. (NASDAQ: ANGO) within the TradingView platform. It also lists the financial data providers and various sections of the TradingView website.", "url": "https://www.tradingview.com/symbols/NASDAQ-ANGO/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T00:40:00", "published_display": "06 Jul 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of AngioDynamics, Inc. \u2013 NASDAQ:ANGO", "summary": "This article provides financial information for AngioDynamics, Inc. (NASDAQ: ANGO), specifically its forward price-to-sales ratio. It lists the company's stock market data and indicates that the market is currently closed with no trades. The core content appears to be a data poin", "url": "https://www.tradingview.com/symbols/NASDAQ-ANGO/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T01:10:04", "published_display": "02 Jul 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of AngioDynamics, Inc. \u2013 LS:A0B9A5", "summary": "This article provides financial data for AngioDynamics, Inc. (A0B9A5) on TradingView, specifically focusing on its forward price-to-sales ratio. It lists market information, financial overviews, and other technical and fundamental data points available for the company.", "url": "https://www.tradingview.com/symbols/LS-A0B9A5/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T00:09:44", "published_display": "02 Jul 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: AngioDynamics to Report Fiscal 2026 Fourth Quarter and Full-Year Financial Results on July 14, 2026", "summary": "AngioDynamics (NASDAQ: ANGO) announced it will report its fiscal 2026 fourth quarter and full-year financial results on Tuesday, July 14, 2026, before the market opens. Management will host a conference call and webcast at 8:00 a.m. EDT to discuss the results and provide a busine", "url": "https://www.moomoo.com/news/post/72261163/press-release-angiodynamics-to-report-fiscal-2026-fourth-quarter-and?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-06-30T21:10:05", "published_display": "30 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics to Report Fiscal 2026 Fourth Quarter and Full-Year Financial Results on July 14, 2026", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/angiodynamics-report-fiscal-2026-fourth-120000778.html", "source_name": "Business Wire", "published_at": "2026-06-30T12:00:00+00:00", "published_display": "30 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics sets July 14 call for fiscal 2026 results", "summary": "AngioDynamics announced it will report its fiscal year 2026 fourth quarter and full-year financial results on July 14, 2026, before market open. The company's management will host a conference call at 8:00 AM ET on the same day to discuss these results. The call details and webca", "url": "https://www.stocktitan.net/news/ANGO/angio-dynamics-to-report-fiscal-2026-fourth-quarter-and-full-year-ndq09n0j8c16.html", "source_name": "Stock Titan", "published_at": "2026-06-30T12:10:46", "published_display": "30 Jun 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics Receives FDA IDE Approval for RELIEF Feasibility Study Evaluating NanoKnife IRE Platform as Minimally Invasive Treatment for Benign Prostatic Hyperplasia (BPH)", "summary": "AngioDynamics has received FDA Investigational Device Exemption (IDE) approval to begin the RELIEF study, evaluating its NanoKnife System for treating benign prostatic hyperplasia (BPH). This feasibility study will assess the irreversible electroporation (IRE) technology as a min", "url": "https://zenopa.com/us/news/angiodynamics-receives-fda-ide-approval-for-relief-feasibility-study-evaluating-nanoknife-ire-platform-as-minimally-invasive-treatment-for-benign-prostatic-hyperplasia-bph", "source_name": "Zenopa", "published_at": "2026-06-27T07:11:04", "published_display": "27 Jun 2026 07:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics, Inc. Actuals & Estimates (NASDAQ:ANGO)", "summary": "This article provides an in-depth financial overview of AngioDynamics, Inc. (NASDAQ:ANGO), including its stock performance, analyst estimates, historical prices, market capitalization, earnings, and revenue. It highlights ANGO's recent stock price increase, upcoming earnings repo", "url": "https://www.tradingview.com/symbols/NASDAQ-ANGO/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T14:42:22", "published_display": "25 Jun 2026 14:42", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANGO Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for AngioDynamics, Inc. (ANGO) stock, including analyst price targets, past performance, and key financial metrics. It highlights that AngioDynamics is expected to release its next earnings report on July 21, 2026, and details previous earnings an", "url": "https://www.tradingview.com/symbols/NASDAQ-ANGO/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T13:10:49", "published_display": "25 Jun 2026 13:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics Port Catheter Lawsuit Claims Woman\u2019s SmartPort Implants Caused Multiple Infections", "summary": "A Georgia woman has filed a lawsuit against AngioDynamics and Navilyst Medical, alleging that two of their SmartPort implants caused her to suffer multiple infections, requiring repeated surgeries. The lawsuit claims that the port catheters were defectively designed and manufactu", "url": "https://www.aboutlawsuits.com/angiodynamics-port-catheter-lawsuit/angiodynamics-port-catheter-lawsuit-smartport-implants-multiple-infections/", "source_name": "AboutLawsuits.com", "published_at": "2026-06-23T14:09:56", "published_display": "23 Jun 2026 14:09", "sentiment": "negative", "sentiment_pct": 14, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Reasons to Hold AngioDynamics Stock in Your Portfolio for Now", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQX0o3ZC16UTRKM3ZrZi1ubHNUUFk4UFJFLXlGeDhnNVpabjdzbmVRaVhWNnNHU3pJUm1LQjVYaTFvNlVZal8xVFFReW9jRFJWc2hfWGVVUzNib1NoRUhJaTNLakJRQTg4WVM3X3dqbTRuUGY3N0t2cXJvc0lMR2t6dWloU1R1dm45dTRXYUhJWFZxRmVfY3FGTk1fSHljTmFUU2pqUw?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics Inc (ANGO) Valuation: PE, PB & Fair Value Analysis", "summary": "The article provides a valuation analysis for AngioDynamics Inc (ANGO), noting its current valuation score of 7.26, which ranks 164th in the Healthcare Equipment & Supplies industry. It highlights the company's current P/E ratio of -16.31, which is significantly below its recent ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ango/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-22T17:39:33", "published_display": "22 Jun 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics Inc (ANGO) Institutional Confidence", "summary": "AngioDynamics Inc (ANGO) has an institutional shareholding score of 10.00, placing it first in the Healthcare Equipment & Supplies industry. The institutional shareholding proportion is currently 93.94%, a decrease of 11.97% quarter-over-quarter. Steven Cohen is the largest insti", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ango/sentiment", "source_name": "TradingKey", "published_at": "2026-06-19T03:39:18", "published_display": "19 Jun 2026 03:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANGO Gains FDA IDE Approval for NanoKnife BPH Feasibility Study", "summary": "AngioDynamics (ANGO) has received FDA IDE approval for its RELIEF study, which will evaluate the NanoKnife System's irreversible electroporation (IRE) technology for treating benign prostatic hyperplasia (BPH). This study expands the NanoKnife's clinical applications beyond oncol", "url": "https://ca.finance.yahoo.com/news/ango-gains-fda-ide-approval-135200995.html", "source_name": "Yahoo! Finance Canada", "published_at": "2026-06-18T09:52:00", "published_display": "18 Jun 2026 09:52", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics Secures FDA Approval to Begin Benign Prostatic Hyperplasia Study", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/angiodynamics-secures-fda-approval-begin-125253702.html", "source_name": "MT Newswires", "published_at": "2026-06-17T12:52:53+00:00", "published_display": "17 Jun 2026 12:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics receives FDA approval for RELIEF clinical study", "summary": "AngioDynamics has received FDA approval for an Investigational Device Exemption to commence its RELIEF clinical study. This study will evaluate the NanoKnife System for treating lower urinary tract symptoms in men with benign prostatic hyperplasia, aiming to generate safety and e", "url": "https://grafa.com/en/news/united-states/angiodynamics-receives-fda-approval-for-relief-study", "source_name": "grafa.com", "published_at": "2026-06-17T12:55:00", "published_display": "17 Jun 2026 12:55", "sentiment": "positive", "sentiment_pct": 77, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics receives FDA approval for BPH treatment study", "summary": "AngioDynamics (NASDAQ:ANGO) has received FDA approval for an Investigational Device Exemption application to commence its RELIEF study, investigating the use of its NanoKnife System for treating benign prostatic hyperplasia (BPH). The study will evaluate the system's irreversible", "url": "https://www.investing.com/news/company-news/angiodynamics-receives-fda-approval-for-bph-treatment-study-93CH-4747325", "source_name": "Investing.com", "published_at": "2026-06-17T12:39:27", "published_display": "17 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics wins FDA okay to test NanoKnife in BPH patients", "summary": "AngioDynamics (NASDAQ: ANGO) has received FDA approval for an Investigational Device Exemption (IDE) to initiate the RELIEF study. This feasibility study will evaluate the company's NanoKnife System, which uses irreversible electroporation (IRE) technology, as a minimally invasiv", "url": "https://www.stocktitan.net/news/ANGO/angio-dynamics-receives-fda-ide-approval-for-relief-feasibility-d9l4kzl09x1h.html", "source_name": "Stock Titan", "published_at": "2026-06-17T12:39:27", "published_display": "17 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics Inc (ANGO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for AngioDynamics Inc (ANGO), detailing its regional revenue contributions. As of the latest update, the data shows that the United States accounts for 85.79% ($67.28M) of the company's revenue, while International operations contribute 1", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ango/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T11:39:27", "published_display": "17 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics gains FDA IDE approval for RELIEF study of NanoKnife System", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPNUNQVkpoVm93ek02U0JEX0xGcThSWkpHSGZhVWhzUkpoUEp3QmxiMmJjZUctb1JUMXVRXzk0ejdSd2k4UzNBdDFGOVBhckRyRlZUcXoyQUlKNm5qQ0JXVjFFLWNzRUpxd2RGX1hkMXYwQmJKc0g5ZThuZmlqVV9peHdfbWk3YnIzdGZTQUdvSzNHVkpMX3REZVpUdHpLQXVPZ2NkRDFXVVRIYmxMUmlMakpsbGdlT0R3?oc=5", "source_name": "scanx.trade", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics (ANGO) Margins Stay Negative In Q2 2026 And Test Bullish Turnaround Hopes", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-03T07:00:00+00:00", "published_display": "03 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANGIODYNAMICS ($ANGO) Releases Q3 2026 Earnings | ANGO Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxPQUMyaGNWN2kzdllPWlh6bkNhbXNUZTh5ek1iZGw3U2t1amVvR0JOLWRrQ0hBTWp5cUpjOEpBQWxUaURoYW9fV3Zza0NzWENJTWtOVkdzRzY1UjdmQ3VhYTRWWE5qUE4yQ1NPWmlLSGpBbkJqM24tMFdjLU9ybzk3SE1qV3ZrTDBmcGRGa2hqdw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics (ANGO) Reports Q3 Loss, Tops Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNQTM0VVl1NGswVnEwX1JiVFBQV29YenpRODJGc1BGaXN5TDQ2OURvcl9kaVcxNWhySEJTYTMxaEFzN0pwOXBFTEtXbXN0YTBZYWoxaWNsSkVnTm52U3NUVk90LXpqYl9WUFBWWGl0RUlOUlNaNTFma1BSaUZpY09iTWxiMFhkNnBsa0p3dTlabHVhbko0ZHNwM19HRDNjTno3?oc=5", "source_name": "Market source", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics Inc (ANGO) Stock Price Today & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE4wUVlQR2M2TDhHZm9RRjRMZV9jUnI0QjI2SWU2VVkwcmt0aV9WN2dWeVJlLThicnE0T25tX3dieHQ1Zl95R1hNNXJ2QTM3YS1MOVRBeFRHTQ?oc=5", "source_name": "Gotrade", "published_at": "2026-01-13T02:24:34+00:00", "published_display": "13 Jan 2026 02:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing AngioDynamics (ANGO) Valuation After Raised Guidance And Med Tech Momentum", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-09T08:00:00+00:00", "published_display": "09 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 68, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why AngioDynamics Stock Is Sinking Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxOU1ZQWkJ4djdhcUMxMm9sZHJrRmVEWjZ0U3RMbkVFQXhBbjcwLTBLTVVOaWJtT0g1VUJ5MWdDSGIyeUVscmZlS3pCOXBiWDNfSVVFN2plbEt5ZklMS0NKbWxiY1JTMGg3eFczeUNoaHNwd05DOEotVlpsZS1TOTFzY2Qtd19SekhMTTYw?oc=5", "source_name": "The Motley Fool", "published_at": "2026-01-06T08:00:00+00:00", "published_display": "06 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANGIODYNAMICS Q2 2026 Earnings Preview: Recent $ANGO Insider Trading, Hedge Fund Activity, and More", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxQSjN2ZFAtYnE2aEpXeFNrY0tJa1lyS3NJS09tMndyb0RMSFFoVjhXZERJZnJLZVFRaHhVQlcwa1NLM0haSWVqN2h5dDNWTUFPbVd2bVgtNl95WjJBMTlrbXNjN3N3TDhJNXM0RC1JbmRCanNxQU1uRHlDNGQ0X1hoUkVvNHVJVk5pV256OGNHek1IYy1KVDJSazlodmxUMVVfdVhMLVJhd1o3OU5OUHVXRmQ5b3ppR2NhdVRNU211a1FnellUQlNRcmtzNFVrdUZnV3V2Y3lSWQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-01-04T08:00:00+00:00", "published_display": "04 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics\u2019 NanoKnife\u00ae System Named to TIME\u2019s 2025 Best Inventions List", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPR2hEbWZucjNaUTNRUzMwdTdNOVE5Z2M0WnpQTmtPLVNsWmRCN0EzRUpCQ21tVWotSVhwaUJqck04c3drOXkwZG9ETzhCdVZBOVlTM3dqRER1MFQybzByRUZ4UENZREo4VzFGZHlySXBuOE11MldieWlna2FoVTRXN3JGQVBNSVNpZEsxRjFhcDZTd2JMTEFUNmpLTXJYWGI2Y2Y0LVV4UmR5UWY3dHMwQ1Jzaw?oc=5", "source_name": "Stock Titan", "published_at": "2025-10-13T07:00:00+00:00", "published_display": "13 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "AngioDynamics rises as Freedom Broker raises stock price target to $17", "summary": "Freedom Broker analysts have raised their price target for AngioDynamics (ANGO) to $17, maintaining a \"Buy\" rating, following strong financial results. The NanoKnife platform is highlighted as a key growth driver, with expanded insurance coverage and increased disposable use. The", "url": "https://fbroker.kz/en/news/50993-angiodynamics-rises-as-freedom-broker-raises-stock-price-target-to-17-en-2", "source_name": "Freedom Broker", "published_at": "2026-07-16T18:42:19", "published_display": "16 Jul 2026 18:42", "sentiment": "positive", "sentiment_pct": 81, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics: Growth Is Working, Price Knows It (Rating Downgrade)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOWXZjMTloZVo2N1pCN0d3R1Y4a1hqMktoT1ZZUTB2dV9KZ2VyQ09XNV9XMWNfS01hZkZrcXdaVm1ETXJTLTFSc3h0MFVma3N5Vkd4VjZnRTlmTmZSaWpmRW14c25PSW9qNy1JWFVfX0VFY1AtamRGekZvNHZ1N2xoNlBYWjZLTkV1dktOYmVhclpOVVJCR2FGVzAwU1ZreEpZQlMw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-16T15:07:15+00:00", "published_display": "16 Jul 2026 15:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Maintains AngioDynamics(ANGO.US) With Buy Rating, Maintains Target Price $19", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNcHdIUkNXSkc4WkhQR0Y3MUhSamZIMmZRTjJrYkwzeXBJY3otaWNCNTRicWF6RjFOR2M0am96aUt3RGRQUWx3QmdPMk5zOEppMkFSRG9oWXpNaWQweUVhcUxuSm1lTGRqVGdOR0Jld2xwLTJHTmVKVWRpc1YxYTZfcUV5Z1ZGMUo0UEY3eDlIc1g3bUZJQWhjWnZGaEQ5OTRWc1J6NE9UaE15WUJLUFFzMHVSVFQ5Zm1uUnFB?oc=5", "source_name": "Moomoo", "published_at": "2026-07-16T12:14:45+00:00", "published_display": "16 Jul 2026 12:14", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright raises AngioDynamics stock price target on growth", "summary": "H.C. Wainwright has increased its price target for AngioDynamics (NASDAQ:ANGO) shares to $19 from $16, maintaining a Buy rating, following the company's strong fiscal fourth-quarter and full-year 2026 results. The medical technology firm reported significant growth in net sales, ", "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-raises-angiodynamics-stock-price-target-on-growth-93CH-4795558", "source_name": "Investing.com", "published_at": "2026-07-16T11:41:36", "published_display": "16 Jul 2026 11:41", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics (ANGO) Stock Faces Profitability Question As Q4 EPS Loss Deepens Bearish Narrative", "summary": "AngioDynamics (ANGO) concluded FY 2026 with a Q4 basic EPS loss of US$0.27 and a full-year basic EPS loss of US$0.88 on US$320.2 million in revenue, continuing a trend of net losses. While forecasts project 72.2% annual earnings growth and profitability within three years, the co", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-ango/angiodynamics/news/angiodynamics-ango-stock-faces-profitability-question-as-q4/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-16T01:13:40", "published_display": "16 Jul 2026 01:13", "sentiment": "negative", "sentiment_pct": 29, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics 4Q Loss/Shr 27c >ANGO", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxOaTNsbDJCNWJyTVRVMG15VnVnNThQNW1hSjQxYkFla1V5TmxjZFBWeV9zaVlra21HYnlvZnRPa0lSd0VYOUZzNDdHM3NyYXZ2WDhTbkpONnRNQ1Zuck1hcXh1aWVzQW5UVDcxTUQ4THl6d3ZYM2l4WUpEdjJfZWRYOWxB?oc=5", "source_name": "Moomoo", "published_at": "2026-07-15T23:36:58+00:00", "published_display": "15 Jul 2026 23:36", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Freedom Broker raises AngioDynamics stock price target to $17 on margin outlook", "summary": "Freedom Broker increased its price target for AngioDynamics (NASDAQ: ANGO) to $17.00 from $16.00, reiterating a Buy rating due to an improved margin outlook. This revision follows an upward adjustment of fiscal 2027 adjusted EBITDA estimates by 29% and expectations of growing mar", "url": "https://www.investing.com/news/analyst-ratings/freedom-broker-raises-angiodynamics-stock-price-target-to-17-on-margin-outlook-93CH-4793769", "source_name": "Investing.com", "published_at": "2026-07-15T15:43:40", "published_display": "15 Jul 2026 15:43", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics Q4 Earnings Beat Estimates, Gross Margin Expands", "summary": "AngioDynamics (ANGO) reported an adjusted loss per share of 7 cents for Q4 fiscal 2026, which was narrower than analysts' expectations, and full-year fiscal 2026 adjusted loss also beat estimates. The company's Q4 revenues rose 8% year-over-year to $86.6 million, exceeding the Za", "url": "https://www.tradingview.com/news/zacks:33dbbdd2c094b:0-angiodynamics-q4-earnings-beat-estimates-gross-margin-expands/", "source_name": "TradingView", "published_at": "2026-07-15T14:43:40", "published_display": "15 Jul 2026 14:43", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics (NASDAQ: ANGO) details device portfolio and risk factors", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOcHlpWDBLTW1QMUVkOEFfVXdkWDQxU0g2dzh2V3VYa0xrTXRoTlh1RUVYLW1VcE5GZVl1M2EzWDhQcnJ1LU5XejhfX1ZZMUF5R2JBVVVpT0kwLS1FWEpkbE5VUHE3a0xFNkxlODk3VFR2VngzcWpqN0l2NnJnSm5IbWZDY2VITnRSOHhOaHRscm5YdXZhSjVzZzg2OE9CRWhRVzItSlZ0WQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-14T20:01:03+00:00", "published_display": "14 Jul 2026 20:01", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics Inc (ANGO) Q4 2026 Earnings Call Highlights: Strong Revenue Growth Amidst Challenges", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/angiodynamics-inc-ango-q4-2026-190032475.html", "source_name": "GuruFocus.com", "published_at": "2026-07-14T19:00:32+00:00", "published_display": "14 Jul 2026 19:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANGIODYNAMICS INC FY 2026: Revenue $320.17M, EPS ($0.88) \u2014 10-K Summary", "summary": "AngioDynamics Inc. reported fiscal year 2026 revenue of $320.17M, a 9.5% increase from the previous year, with a net loss of ($36.74M) and diluted loss per share of ($0.88). The revenue growth was primarily driven by Med Tech, and the company is restructuring its manufacturing fo", "url": "https://www.tradingview.com/news/tradingview:0e756c4cf93a3:0-angiodynamics-inc-fy-2026-revenue-320-17m-eps-0-88-10-k-summary/", "source_name": "TradingView", "published_at": "2026-07-14T19:40:08", "published_display": "14 Jul 2026 19:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics Q4 2026 Earnings Call Transcript", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxQQVdpdkhsYzc3MWFCV3l2MkhlNFFUZFdiNFJKRExlV3lvUlNXU3p5QjlvZ19rWU04WXZxWEg2azVvazZfVm80U0didnh2ZzVjMUlNRzVkNF9ORXFLYTlzT21wXzkwcy1NOS1uaHlPTXV1QXBlNmVZV2NuaUdzSnRZY3ZkcUM?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-14T17:12:21+00:00", "published_display": "14 Jul 2026 17:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is AngioDynamics Inc (ANGO) Overvalued After Q4 Earnings Miss? E", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxQS2F1cTBoWjBYTGhZQWptUndkWjl1NEVDWDZmR0ZJZ1J5UUZSbE9GQWIwbE1vT25NZDdvak9mbm96ZzJWdnNRQVZXckEtYzlpUmlrQXpKT1k4QzJ3Sm1yT3B3RkJ6bGlEcWdfZWdmX0FFX0N0dWhVbUx2SEcycVkzLXVYUnZzRG4wbk1Fa0tqaGpiQnJYc1JrQzdydTJjbTBaTTNDS3BwdE5oU3FUeklTYjdJazlXbmxRNVNSRlhTSmdSOEtienhxWnU4MDZfZU5HXzl5d2ZmUWZwdjJqUlNZcXNZdllHSFhoWGVrYlNvVDY?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-14T13:33:55+00:00", "published_display": "14 Jul 2026 13:33", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: AngioDynamics beats Q4 2026 estimates, shares rise", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxNS1FDSjdQOFlCc1hlMVJlNldrUEpFcWhqUFZZMEE3VUNDUVlZQXBCWlQ5X3FsMi01V1ZmU0EtODFrdDk1SnR0Ujc2Vlo4bHl4amtMZWxNb1NjRVI3NXZxbEd3Q2hKQTFUMmVTSTJRb19TQnJmdzZOblhJZzNRck5nd0IyU1FDd3hheVhzbkJJZ3RxcnRKMHZONHoyUFJmWXJpSTRzMzJ0dUo4V3pBMDJnODRrMFlmNzVoNml2RHJMbUhzaEJ5Z1hMVlp3?oc=5", "source_name": "Investing.com", "published_at": "2026-07-14T13:25:56+00:00", "published_display": "14 Jul 2026 13:25", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics Q4 Earnings Call Highlights", "summary": "", "url": "https://finance.yahoo.com/m/4216e10c-f951-375d-873d-0df91320a7c6/angiodynamics-q4-earnings.html", "source_name": "MarketBeat", "published_at": "2026-07-14T13:03:07+00:00", "published_display": "14 Jul 2026 13:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics, Inc. 2026 Q4 - Results - Earnings Call Presentation (NASDAQ:ANGO) 2026-07-14", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNWDdzbVZ6WDVDOVoxRzRjeXFyV2c2bXBwNmZYUFgxUHNwd0dyeTJFeVNvaHRZS3NoWVFXRUJKNFdZYWhQa2RRWkIwTDQtMHBvbnV1MHNmR2hOSXMybFBrTnpZM1lFdmVuTEl1ek5EQURmTjFWaHFSZktSUWpWM29BNzIxeEsxZjczVWUtakRxTnFHWUtsOGtMUTdKNTdlZHpYZGJN?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-14T12:31:57+00:00", "published_display": "14 Jul 2026 12:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics tops revenue forecasts and raises sales outlook for fiscal 2027 (ANGO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9AFBVV95cUxPenlCdmhNVFZuZWQxOGtELUxNQmZHcXc2UWxXODVTU1FYSDlGVUpzS05QSlBBS3ZPZ1ZFVUJIQ2thYzlEcGszbUhKd3dNakFEdUFmV3BrdmlnY1MtMkFwQWEwSE05YlFHeUtSQTJKUXpTZlNxUzhTcnFZOXcwUklOZUVzYVRseS1fdjgyYXNmTmR6X1RlZW9vWFJSOTlwRUtIQ3EzVHRab0pBdW1UNm1sM0gzRjJBcUdHRmttTGtuM0V0MGlxUlhUUkl2dTdTX3JuS2Nvdm5MZzBJQUU2UUNiSzFxM1QwM2JadmU4Q2xDT2tsMHZT?oc=5", "source_name": "MSN", "published_at": "2026-07-14T11:39:57+00:00", "published_display": "14 Jul 2026 11:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics Releases Q4 2026 Financial Results", "summary": "AngioDynamics, Inc. (ANGO) reported Q4 2026 adjusted diluted loss per share of -$0.07, outperforming the -$0.09 expected loss. The company's revenue reached $86.6 million, surpassing the consensus estimate by 7.9% and marking an 8% year-over-year increase. AngioDynamics also prov", "url": "https://news.alphastreet.com/angiodynamics-releases-q4-2026-financial-results/", "source_name": "AlphaStreet", "published_at": "2026-07-14T12:23:25", "published_display": "14 Jul 2026 12:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics (ANGO) Reports Q4 Loss, Beats Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNb2R0ZTJ2RkJvbW9WbE5YTXNfM1pZWEx4NjlNVGNkZzhYOG90a2tpWTRabEhhaUJQV0lPQWNadnlocFcydGhKQ2dMV3dGYWdFSC1uMENTZjhIVVlXMTdrZ09GZzRYVG1tYmlYOXlfVURvMnJRaWlNdURDYnhZN2dUclBRSTNzRlRObFpRa25vVUFDTnRyczhPTXRydzZhTVha?oc=5", "source_name": "Market source", "published_at": "2026-07-14T11:15:02+00:00", "published_display": "14 Jul 2026 11:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANGIODYNAMICS ($ANGO) Releases Q4 2026 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxNaGw3SC1qWDNDdjhlbEZKcm9mVVdleGk2QUtTWVF3U1R3dVc4VlVDbHZKdF9XNmVTanJGdkQyWUZqbnF0dDhRME9zTDY3TWQ2aGtZWENTVDdnSEo3M2xJb1dCQnFZNExXWmJCM3VzdDlMV2NaMkNROHhfS1RzMUtyY2xoYUNZRUJjNmp3Mm1yRQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-14T10:30:00+00:00", "published_display": "14 Jul 2026 10:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Record 2026 sales as AngioDynamics (NASDAQ: ANGO) grows Med Tech 18%", "summary": "AngioDynamics (NASDAQ: ANGO) reported record fiscal 2026 results with pro forma net sales of $320.2 million, a 9.4% increase, driven by an 18.4% rise in Med Tech revenue. Despite a GAAP net loss of $36.7 million, adjusted EBITDA increased to $13.2 million. The company issued fisc", "url": "https://www.stocktitan.net/sec-filings/ANGO/8-k-angiodynamics-inc-reports-material-event-12136bb69c7f.html", "source_name": "Stock Titan", "published_at": "2026-07-14T11:14:25", "published_display": "14 Jul 2026 11:14", "sentiment": "positive", "sentiment_pct": 69, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results; Continued Execution Drives Med Tech Growth and Full-Year Profitability", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/angiodynamics-reports-record-fiscal-2026-100000723.html", "source_name": "Business Wire", "published_at": "2026-07-14T10:00:00+00:00", "published_display": "14 Jul 2026 10:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NanoKnife Medicare Coverage Takes Effect for Qualifying Patients", "summary": "AngioDynamics (NASDAQ: ANGO) announced its fourth quarter and full fiscal year 2026 financial results, highlighting a year of consistent execution and significant growth in its Med Tech segment. The company reported full-year Med Tech growth over 18%, driven by platform technolog", "url": "https://www.stocktitan.net/news/ANGO/angio-dynamics-reports-record-fiscal-year-2026-fourth-quarter-and-yawzx4si7ilh.html", "source_name": "Stock Titan", "published_at": "2026-07-14T10:14:25", "published_display": "14 Jul 2026 10:14", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: AngioDynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results", "summary": "AngioDynamics reported record financial results for its fiscal year 2026 fourth quarter and full year. The company saw strong performance driven by its innovative medical technologies. These results highlight a period of significant growth and market penetration for AngioDynamics", "url": "https://www.moomoo.com/news/post/72924322/press-release-angiodynamics-reports-record-fiscal-year-2026-fourth-quarter?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-14T10:14:25", "published_display": "14 Jul 2026 10:14", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics: Fiscal Q4 Earnings Snapshot", "summary": "AngioDynamics Inc. (ANGO) reported a fiscal fourth-quarter loss of $11.4 million, or 27 cents per share, with adjusted losses at 7 cents per share. The medical device maker posted revenue of $86.6 million for the quarter. For the full year, the company's loss widened to $36.7 mil", "url": "https://www.10tv.com/article/syndication/associatedpress/angiodynamics-fiscal-q4-earnings-snapshot/616-5559f4da-9b02-4d23-9dea-65e182193575", "source_name": "10TV", "published_at": "2026-07-14T06:18:00", "published_display": "14 Jul 2026 06:18", "sentiment": "negative", "sentiment_pct": 32, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics Inc expected to post a loss of 9 cents a share - Earnings Preview", "summary": "AngioDynamics Inc is projected to report a loss of 9 cents per share, according to this earnings preview. The article, sourced from Reuters, specifically highlights the anticipated financial performance for the company. Readers are prompted to start a free trial to access the ful", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_L8N43C0WC:0-angiodynamics-inc-expected-to-post-a-loss-of-9-cents-a-share-earnings-preview/", "source_name": "TradingView", "published_at": "2026-07-10T12:40:48", "published_display": "10 Jul 2026 12:40", "sentiment": "negative", "sentiment_pct": 28, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vortex Port Lawsuit Claims Defective AngioDynamics Device Caused Infection, Pulmonary Embolism", "summary": "A South Carolina woman has filed a lawsuit against AngioDynamics and Navilyst Medical Inc., alleging that their defective Vortex port catheter caused her to suffer pulmonary embolisms and a serious infection, necessitating its surgical removal. The complaint claims the defendants", "url": "https://www.aboutlawsuits.com/angiodynamics-port-catheter-lawsuit/vortex-port-lawsuit-defective-angiodynamics-device-infection-pulmonary-embolism/", "source_name": "AboutLawsuits.com", "published_at": "2026-07-07T15:11:00", "published_display": "07 Jul 2026 15:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics (Nasdaq:ANGO) - Stock Analysis", "summary": "This report provides a comprehensive stock analysis of AngioDynamics (Nasdaq:ANGO), detailing its financial performance, future growth prospects, and recent developments. The company, a medical technology firm specializing in devices for peripheral vascular disease and oncology, ", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-ango/angiodynamics", "source_name": "Simply Wall Street", "published_at": "2026-07-07T11:40:01", "published_display": "07 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of AngioDynamics, Inc. \u2013 NASDAQ:ANGO", "summary": "This article provides the \"Price to earnings forward\" value for AngioDynamics, Inc. (NASDAQ: ANGO) within the TradingView platform. It also lists the financial data providers and various sections of the TradingView website.", "url": "https://www.tradingview.com/symbols/NASDAQ-ANGO/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T00:40:00", "published_display": "06 Jul 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of AngioDynamics, Inc. \u2013 NASDAQ:ANGO", "summary": "This article provides financial information for AngioDynamics, Inc. (NASDAQ: ANGO), specifically its forward price-to-sales ratio. It lists the company's stock market data and indicates that the market is currently closed with no trades. The core content appears to be a data poin", "url": "https://www.tradingview.com/symbols/NASDAQ-ANGO/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T01:10:04", "published_display": "02 Jul 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of AngioDynamics, Inc. \u2013 LS:A0B9A5", "summary": "This article provides financial data for AngioDynamics, Inc. (A0B9A5) on TradingView, specifically focusing on its forward price-to-sales ratio. It lists market information, financial overviews, and other technical and fundamental data points available for the company.", "url": "https://www.tradingview.com/symbols/LS-A0B9A5/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T00:09:44", "published_display": "02 Jul 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: AngioDynamics to Report Fiscal 2026 Fourth Quarter and Full-Year Financial Results on July 14, 2026", "summary": "AngioDynamics (NASDAQ: ANGO) announced it will report its fiscal 2026 fourth quarter and full-year financial results on Tuesday, July 14, 2026, before the market opens. Management will host a conference call and webcast at 8:00 a.m. EDT to discuss the results and provide a busine", "url": "https://www.moomoo.com/news/post/72261163/press-release-angiodynamics-to-report-fiscal-2026-fourth-quarter-and?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-06-30T21:10:05", "published_display": "30 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics to Report Fiscal 2026 Fourth Quarter and Full-Year Financial Results on July 14, 2026", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/angiodynamics-report-fiscal-2026-fourth-120000778.html", "source_name": "Business Wire", "published_at": "2026-06-30T12:00:00+00:00", "published_display": "30 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics sets July 14 call for fiscal 2026 results", "summary": "AngioDynamics announced it will report its fiscal year 2026 fourth quarter and full-year financial results on July 14, 2026, before market open. The company's management will host a conference call at 8:00 AM ET on the same day to discuss these results. The call details and webca", "url": "https://www.stocktitan.net/news/ANGO/angio-dynamics-to-report-fiscal-2026-fourth-quarter-and-full-year-ndq09n0j8c16.html", "source_name": "Stock Titan", "published_at": "2026-06-30T12:10:46", "published_display": "30 Jun 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics Receives FDA IDE Approval for RELIEF Feasibility Study Evaluating NanoKnife IRE Platform as Minimally Invasive Treatment for Benign Prostatic Hyperplasia (BPH)", "summary": "AngioDynamics has received FDA Investigational Device Exemption (IDE) approval to begin the RELIEF study, evaluating its NanoKnife System for treating benign prostatic hyperplasia (BPH). This feasibility study will assess the irreversible electroporation (IRE) technology as a min", "url": "https://zenopa.com/us/news/angiodynamics-receives-fda-ide-approval-for-relief-feasibility-study-evaluating-nanoknife-ire-platform-as-minimally-invasive-treatment-for-benign-prostatic-hyperplasia-bph", "source_name": "Zenopa", "published_at": "2026-06-27T07:11:04", "published_display": "27 Jun 2026 07:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics, Inc. Actuals & Estimates (NASDAQ:ANGO)", "summary": "This article provides an in-depth financial overview of AngioDynamics, Inc. (NASDAQ:ANGO), including its stock performance, analyst estimates, historical prices, market capitalization, earnings, and revenue. It highlights ANGO's recent stock price increase, upcoming earnings repo", "url": "https://www.tradingview.com/symbols/NASDAQ-ANGO/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T14:42:22", "published_display": "25 Jun 2026 14:42", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANGO Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for AngioDynamics, Inc. (ANGO) stock, including analyst price targets, past performance, and key financial metrics. It highlights that AngioDynamics is expected to release its next earnings report on July 21, 2026, and details previous earnings an", "url": "https://www.tradingview.com/symbols/NASDAQ-ANGO/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T13:10:49", "published_display": "25 Jun 2026 13:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics Port Catheter Lawsuit Claims Woman\u2019s SmartPort Implants Caused Multiple Infections", "summary": "A Georgia woman has filed a lawsuit against AngioDynamics and Navilyst Medical, alleging that two of their SmartPort implants caused her to suffer multiple infections, requiring repeated surgeries. The lawsuit claims that the port catheters were defectively designed and manufactu", "url": "https://www.aboutlawsuits.com/angiodynamics-port-catheter-lawsuit/angiodynamics-port-catheter-lawsuit-smartport-implants-multiple-infections/", "source_name": "AboutLawsuits.com", "published_at": "2026-06-23T14:09:56", "published_display": "23 Jun 2026 14:09", "sentiment": "negative", "sentiment_pct": 14, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Reasons to Hold AngioDynamics Stock in Your Portfolio for Now", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQX0o3ZC16UTRKM3ZrZi1ubHNUUFk4UFJFLXlGeDhnNVpabjdzbmVRaVhWNnNHU3pJUm1LQjVYaTFvNlVZal8xVFFReW9jRFJWc2hfWGVVUzNib1NoRUhJaTNLakJRQTg4WVM3X3dqbTRuUGY3N0t2cXJvc0lMR2t6dWloU1R1dm45dTRXYUhJWFZxRmVfY3FGTk1fSHljTmFUU2pqUw?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics Inc (ANGO) Valuation: PE, PB & Fair Value Analysis", "summary": "The article provides a valuation analysis for AngioDynamics Inc (ANGO), noting its current valuation score of 7.26, which ranks 164th in the Healthcare Equipment & Supplies industry. It highlights the company's current P/E ratio of -16.31, which is significantly below its recent ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ango/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-22T17:39:33", "published_display": "22 Jun 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics Inc (ANGO) Institutional Confidence", "summary": "AngioDynamics Inc (ANGO) has an institutional shareholding score of 10.00, placing it first in the Healthcare Equipment & Supplies industry. The institutional shareholding proportion is currently 93.94%, a decrease of 11.97% quarter-over-quarter. Steven Cohen is the largest insti", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ango/sentiment", "source_name": "TradingKey", "published_at": "2026-06-19T03:39:18", "published_display": "19 Jun 2026 03:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANGO Gains FDA IDE Approval for NanoKnife BPH Feasibility Study", "summary": "AngioDynamics (ANGO) has received FDA IDE approval for its RELIEF study, which will evaluate the NanoKnife System's irreversible electroporation (IRE) technology for treating benign prostatic hyperplasia (BPH). This study expands the NanoKnife's clinical applications beyond oncol", "url": "https://ca.finance.yahoo.com/news/ango-gains-fda-ide-approval-135200995.html", "source_name": "Yahoo! Finance Canada", "published_at": "2026-06-18T09:52:00", "published_display": "18 Jun 2026 09:52", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics Secures FDA Approval to Begin Benign Prostatic Hyperplasia Study", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/angiodynamics-secures-fda-approval-begin-125253702.html", "source_name": "MT Newswires", "published_at": "2026-06-17T12:52:53+00:00", "published_display": "17 Jun 2026 12:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics receives FDA approval for RELIEF clinical study", "summary": "AngioDynamics has received FDA approval for an Investigational Device Exemption to commence its RELIEF clinical study. This study will evaluate the NanoKnife System for treating lower urinary tract symptoms in men with benign prostatic hyperplasia, aiming to generate safety and e", "url": "https://grafa.com/en/news/united-states/angiodynamics-receives-fda-approval-for-relief-study", "source_name": "grafa.com", "published_at": "2026-06-17T12:55:00", "published_display": "17 Jun 2026 12:55", "sentiment": "positive", "sentiment_pct": 77, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics receives FDA approval for BPH treatment study", "summary": "AngioDynamics (NASDAQ:ANGO) has received FDA approval for an Investigational Device Exemption application to commence its RELIEF study, investigating the use of its NanoKnife System for treating benign prostatic hyperplasia (BPH). The study will evaluate the system's irreversible", "url": "https://www.investing.com/news/company-news/angiodynamics-receives-fda-approval-for-bph-treatment-study-93CH-4747325", "source_name": "Investing.com", "published_at": "2026-06-17T12:39:27", "published_display": "17 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics wins FDA okay to test NanoKnife in BPH patients", "summary": "AngioDynamics (NASDAQ: ANGO) has received FDA approval for an Investigational Device Exemption (IDE) to initiate the RELIEF study. This feasibility study will evaluate the company's NanoKnife System, which uses irreversible electroporation (IRE) technology, as a minimally invasiv", "url": "https://www.stocktitan.net/news/ANGO/angio-dynamics-receives-fda-ide-approval-for-relief-feasibility-d9l4kzl09x1h.html", "source_name": "Stock Titan", "published_at": "2026-06-17T12:39:27", "published_display": "17 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics Inc (ANGO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for AngioDynamics Inc (ANGO), detailing its regional revenue contributions. As of the latest update, the data shows that the United States accounts for 85.79% ($67.28M) of the company's revenue, while International operations contribute 1", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ango/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T11:39:27", "published_display": "17 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics gains FDA IDE approval for RELIEF study of NanoKnife System", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPNUNQVkpoVm93ek02U0JEX0xGcThSWkpHSGZhVWhzUkpoUEp3QmxiMmJjZUctb1JUMXVRXzk0ejdSd2k4UzNBdDFGOVBhckRyRlZUcXoyQUlKNm5qQ0JXVjFFLWNzRUpxd2RGX1hkMXYwQmJKc0g5ZThuZmlqVV9peHdfbWk3YnIzdGZTQUdvSzNHVkpMX3REZVpUdHpLQXVPZ2NkRDFXVVRIYmxMUmlMakpsbGdlT0R3?oc=5", "source_name": "scanx.trade", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics (ANGO) Margins Stay Negative In Q2 2026 And Test Bullish Turnaround Hopes", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-03T07:00:00+00:00", "published_display": "03 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANGIODYNAMICS ($ANGO) Releases Q3 2026 Earnings | ANGO Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxPQUMyaGNWN2kzdllPWlh6bkNhbXNUZTh5ek1iZGw3U2t1amVvR0JOLWRrQ0hBTWp5cUpjOEpBQWxUaURoYW9fV3Zza0NzWENJTWtOVkdzRzY1UjdmQ3VhYTRWWE5qUE4yQ1NPWmlLSGpBbkJqM24tMFdjLU9ybzk3SE1qV3ZrTDBmcGRGa2hqdw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics (ANGO) Reports Q3 Loss, Tops Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNQTM0VVl1NGswVnEwX1JiVFBQV29YenpRODJGc1BGaXN5TDQ2OURvcl9kaVcxNWhySEJTYTMxaEFzN0pwOXBFTEtXbXN0YTBZYWoxaWNsSkVnTm52U3NUVk90LXpqYl9WUFBWWGl0RUlOUlNaNTFma1BSaUZpY09iTWxiMFhkNnBsa0p3dTlabHVhbko0ZHNwM19HRDNjTno3?oc=5", "source_name": "Market source", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics Inc (ANGO) Stock Price Today & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE4wUVlQR2M2TDhHZm9RRjRMZV9jUnI0QjI2SWU2VVkwcmt0aV9WN2dWeVJlLThicnE0T25tX3dieHQ1Zl95R1hNNXJ2QTM3YS1MOVRBeFRHTQ?oc=5", "source_name": "Gotrade", "published_at": "2026-01-13T02:24:34+00:00", "published_display": "13 Jan 2026 02:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing AngioDynamics (ANGO) Valuation After Raised Guidance And Med Tech Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxQNGNZbU12eGFoSXNSenB6TEU2ZzhDTDFlUEtnSTBidHNKY0t1UjJoRVNHSU14NHhNYlA5Vlk5MktGdkg3VTQ4WDQ2bDdQX3huX05fZE9XYWRnNDBjMEhTMGRkdTN5Z2JtTlk2c2NOTkh4dVR3WTFuZHhyZmdfN3VTazhWOUwyS0xZekg0WVF6RHZhV1JNMjlGNWdhWHdlaVh5SzlKYWJHZ1NlODNyN05WNGNnTmphLUs1YXBnMzlrcXVZclI0S2VZQ0xCLVIyWkXSAdQBQVVfeXFMTlFTYi1sWmZiM3p5ZDJWQ19PR3VYZEd0ZGZlU2dwVmh0TGowQ2wzbVE3Um8yVXBKNFRHeVl2aHJEbV9DMVEwNHpqY3NFZHFVUm5kdlcxTFh0aExIa2tyc3dGNGtuWlFQb0htRF83QmI3MWNRNVBwMFdsQU55dWdrUkZKN3NoQ2JmWGlodnpzVFdXdmJTUUpyRWM3VE9EYVc1LTZJdS1iZWRoY18zalU3V3RTTDE0ck4tbm9Qd3dFX193OV9SQTh5dldsTi1uYlRfUkxmUHM?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-09T08:00:00+00:00", "published_display": "09 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 68, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why AngioDynamics Stock Is Sinking Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxOU1ZQWkJ4djdhcUMxMm9sZHJrRmVEWjZ0U3RMbkVFQXhBbjcwLTBLTVVOaWJtT0g1VUJ5MWdDSGIyeUVscmZlS3pCOXBiWDNfSVVFN2plbEt5ZklMS0NKbWxiY1JTMGg3eFczeUNoaHNwd05DOEotVlpsZS1TOTFzY2Qtd19SekhMTTYw?oc=5", "source_name": "The Motley Fool", "published_at": "2026-01-06T08:00:00+00:00", "published_display": "06 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANGIODYNAMICS Q2 2026 Earnings Preview: Recent $ANGO Insider Trading, Hedge Fund Activity, and More", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxQSjN2ZFAtYnE2aEpXeFNrY0tJa1lyS3NJS09tMndyb0RMSFFoVjhXZERJZnJLZVFRaHhVQlcwa1NLM0haSWVqN2h5dDNWTUFPbVd2bVgtNl95WjJBMTlrbXNjN3N3TDhJNXM0RC1JbmRCanNxQU1uRHlDNGQ0X1hoUkVvNHVJVk5pV256OGNHek1IYy1KVDJSazlodmxUMVVfdVhMLVJhd1o3OU5OUHVXRmQ5b3ppR2NhdVRNU211a1FnellUQlNRcmtzNFVrdUZnV3V2Y3lSWQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-01-04T08:00:00+00:00", "published_display": "04 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AngioDynamics\u2019 NanoKnife\u00ae System Named to TIME\u2019s 2025 Best Inventions List", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPR2hEbWZucjNaUTNRUzMwdTdNOVE5Z2M0WnpQTmtPLVNsWmRCN0EzRUpCQ21tVWotSVhwaUJqck04c3drOXkwZG9ETzhCdVZBOVlTM3dqRER1MFQybzByRUZ4UENZREo4VzFGZHlySXBuOE11MldieWlna2FoVTRXN3JGQVBNSVNpZEsxRjFhcDZTd2JMTEFUNmpLTXJYWGI2Y2Y0LVV4UmR5UWY3dHMwQ1Jzaw?oc=5", "source_name": "Stock Titan", "published_at": "2025-10-13T07:00:00+00:00", "published_display": "13 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 90, "total_relevant": 56, "sentiment_summary": {"positive": 23, "negative": 9, "neutral": 24, "score": 55, "total": 56, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "earnings", "primary_label": "Earnings", "confidence": 77, "events": [{"event": "earnings", "label": "Earnings", "weight": 15.75, "count": 28}, {"event": "general", "label": "Market update", "weight": 6.95, "count": 12}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 4.95, "count": 9}, {"event": "analyst", "label": "Analyst action", "weight": 3.65, "count": 6}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 23, "negative_events": 9}, "market_context": {"has_market_context": true, "latest_close": 12.79, "latest_week": "2026-07-10", "one_week_move": -2.3, "four_week_move": 5.7, "twelve_week_move": 17.8, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.228646, "market_dynamics_buy_signal": false, "relative_strength": -1.662002, "fair_value_gap": 44.0, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 47.1792, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-2.3% over one week, +5.7% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 63, "badges": [], "opportunities": [], "risks": [], "event_label": "Earnings", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 8}, {"label": "Stock Titan", "count": 6}, {"label": "Moomoo", "count": 4}, {"label": "Investing.com", "count": 4}, {"label": "Quiver Quantitative", "count": 3}, {"label": "TradingKey", "count": 3}, {"label": "Seeking Alpha", "count": 2}, {"label": "Simply Wall Street", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 56}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 28}, {"label": "Market update", "count": 12}, {"label": "Regulatory and legal", "count": 9}, {"label": "Analyst action", "count": 6}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "55/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Earnings", "tone": "neutral", "text": "77/100 classification confidence."}, {"label": "Company focus", "value": "56", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "3", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-2.3% over one week, +5.7% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "AngioDynamics rises as Freedom Broker raises stock price target to $17"}], "updated_at": "2026-07-17T04:21:48.599042+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}